Tower Research Capital (TRC)’s ENDRA Life Sciences NDRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$309	Buy	+58	New	+$295	﹤0.01%	5072
2025 Q4	–	Sell	-225	Closed	-$1.21K	–	5440
2025 Q3	$1.21K	Buy	+225	New	+$1.18K	﹤0.01%	4844
2025 Q2	–	Sell	-1,130	Closed	-$4.63K	–	5467
2025 Q1	$4.63K	Buy	+1,130	New	+$5.47K	﹤0.01%	4227
2024 Q4	–	Sell	-466	Closed	-$3.28K	–	5898
2024 Q3	$3.28K	Buy	466 +447	+2,353%	+$34.6K	﹤0.01%	4873
2024 Q2	$3.3K	Buy	19 +14	+280%	+$6.03K	﹤0.01%	4906
2024 Q1	$5.02K	Buy	5 +3	+150%	+$5.88K	﹤0.01%	4595
2023 Q4	$6.32K	Sell	2 -2	-50%	-$4.21K	﹤0.01%	4757
2023 Q3	$8.24K	Buy	4 +3	+300%	+$6.41K	﹤0.01%	4371
2023 Q2	$3.49K	Buy	+1	New	+$2.82K	﹤0.01%	5066
2023 Q1	–	Hold	0	–	–	–	6123
2022 Q4	–	Sell	-1	Closed	-$8.38K	–	6197
2022 Q3	$8K	Hold	1	–	–	﹤0.01%	4796
2022 Q2	$9K	Hold	1	–	–	﹤0.01%	4574
2022 Q1	$8K	Buy	+1	New	+$17.9K	﹤0.01%	4598
2021 Q4	–	Hold	0	–	–	–	6415
2021 Q3	–	Hold	0	–	–	–	6025

Other funds holding NDRA

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Tower Research Capital (TRC)'s NDRA Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in ENDRA Life Sciences (NDRA) in Q2 2026: 58 shares worth $309. The stake represents ﹤0.01% of the portfolio and ranks #5072 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in NDRA as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in NDRA in Q1 2022 and has held it in 12 quarters since. The position peaked at $9K in Q2 2022. 10 funds tracked by Wall St. Rank hold NDRA as of Q2 2026.

Tower Research Capital (TRC) held 58 shares of ENDRA Life Sciences worth $309 as of Q2 2026.
ENDRA Life Sciences was a new Tower Research Capital (TRC) position in Q2 2026.
ENDRA Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5072 holding.
Tower Research Capital (TRC) first reported a position in ENDRA Life Sciences in Q1 2022 and has held it in 12 quarters since.
Tower Research Capital (TRC)'s ENDRA Life Sciences position peaked at $9K in Q2 2022.
10 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.